Modulation of cancer pathways by inhibitors of guanylate metabolism

Advances in Enzyme Regulation

Volumn 46, Issue 1, 2006, Pages 176-190

  Oláh, Edith ^a   Kökény, Szabolcs ^a   Papp, János ^a   Bozsik, Anikó ^a   Keszei, Márton ^b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANOSINE PHOSPHATE; INOSINATE DEHYDROGENASE; RIBAVIRIN; TIAZOFURIN;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

5'-GUANYLIC ACID; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; HUMANS; IMP DEHYDROGENASE; NEOPLASMS; RIBAVIRIN; SIGNAL TRANSDUCTION;

EID: 33748031402     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2006.01.002     Document Type: Article

References (65)

1. Abonyi M.E., and Lakatos P. Ribavirin in the treatment of hepatitis C. Anticancer Res 25 (2005) 1315-1320
2. Billi A.M., Cocco L., Martelli A.M., Gilmour R.S., and Weber G. Tiazofurin-induced changes in inositol lipid cycle in nuclei of Friend erythroleukemia cells. Biochem Biophys Res Commun 1 (1993) 8-12
3. Bishop J.M. The molecular genetics of cancer. Science 235 (1987) 305-311
4. Bishop J.M. Molecular themes in oncogenesis. Cell 64 (1991) 235-248
5. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., et al. Essential role for oncogenetic Ras in tumour maintenance. Nature 400 (1999) 468-472
6. Cocco L., Capitani S., Maraldi N.M., Mazzotti G., Barnabei O., Gilmour R.S., et al. Inositol lipid cycle and autonomous nuclear signalling. Adv Enzyme Regul 36 (1996) 101-114
7. Cooney D.A., Jayaram H.N., Gebeyehu G., Betts C.R., Kelley J.A., Marquez V.E., et al. The conversion of 2-β-d-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase inhibitory properties. Biochem Pharmacol 31 (1982) 2133-2136
8. Cory S. Activation of cellular oncogenes in hemopoletic cells by chromosome translocation. Adv Cancer Res 47 (1986) 189-234
9. Csokay B., Pajj J., Besznyák I., Bosze P., Sárosi Zs., Tóth J., et al. Oncogene patterns in breast and ovarian carcinomas. Eur J Surg Oncol 19 (1993) 593-599
10. Csokay B., Prajda N., Weber G., and Olah E. Molecular mechanisms in the antiproliferative action of quercetin. Life Sci 60 (1997) 2157-2163
11. Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. In: Hematology (Am Soc Hematol Educ Program) 2001; p. 87-112.
12. Felsher D.W. Opinion: cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 3 (2003) 375-379
13. Felsher D.W. Reversibility of oncogene-induced cancer. Curr Opin Genet Develop 14 (2004) 37-42
14. Felsher D.W., and Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4 (1999) 199-207
15. Fisher G.H., Wellan S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Gene Dev 15 (2001) 3249-3262
16. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., et al. A census of human cancer genes. Nat Rev Cancer 4 (2004) 177-183
17. Gunther E.J., Moody S.E., Belka G.K., Hahn K.T., Innocent N., Dugan K.D., et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Gene Dev 17 (2003) 488-501
18. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
19. Harrison S.D., O'Dwyer P.J., and Trades M.W. Therapeutic synergism of tiazofurin and selected antitumor drugs against sneisitive and resistant P388 leukemia in mice. Cancer Res 46 (1986) 3396-3400
20. Jackson R.C., Weber G., and Morris H.P. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256 (1975) 331-333
21. Jain M., Arvanitis C., Chu K., Devey W., Leonhardt E., Trinh M., et al. Sustained loss of a neoplastic phenotype by brief inatu{combining double acute accent}ctivation of MYC. Science 297 (2002) 102-104
22. Jayaram H.N., Dion R.L., Glazer R.I., Johns D.G., Robins R.K., Srivastava P.C., et al. Initial studies on the mechanisms of action of a new oncolytic thiazole nucleoside, 2-β-d-ribofuranosylthiazole-4-carboxamide (NSC-286193). Biochem Pharmacol 31 (1982) 2371-2380
23. Karlsson A., Giuriato S., Tang F., Fung-Weler J., Levan G., and Felsher D.W. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel choromosomal translocations. Blood 101 (2003) 2797-2803
24. Kokeny Sz., Papp J., Bozsik A., Weber G., and Olah E. Molecular pathways associated with antitumor activity of ribavirin (Riba). Proc Am Assoc Cancer Res 46 (2005) 1378
25. Konno Y., Natsumeda Y., Nagai M., Yamaji Y., Ohno S., Suzuki K., et al. Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines. J Biol Chem 266 (1991) 506-509
26. Kuttan R., Robins R.K., and Saunders P.O. Inhibition of inosinate dehydrogenase by metabolites of 2-β-d-ribofuranosylthiazole-4-carboxamide. Biochem Biophys Res Commun 107 (1982) 862-868
27. Langer C.J. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys 58 (2004) 991-1002
28. Lapis K.Y., Bocsi J., Tovari J., Bartha I., Timar J., and Raso E. Antiinvasive effects of Tiazofurin on liver-metastatic human colon carcinoma xenografts. Anticancer Res 16 6A (1996) 3323-3331
29. Li W., Shen F., and Weber G. Ribavirin and quercetin synergistically downregulate signal transduction and are cytotoxic in human ovarian carcinoma cells. Oncol Res 11 (1999) 243-247
30. Li W., and Weber G. Synergistic action of tiazofurin and genistein on growth inhibition and differentiation of K562 human leukemic cells. Life Sci 22 (1998) 1975-1981
31. Lui M.S., Faderan M.A., Liepnieks J.J., Natsumeda Y., Olah E., Jayaram H.N., et al. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-β-d-ribofuranosylthiazole-4-carboxamide). J Biol Chem 259 (1984) 5078-5082
32. Malek K., Boosalis M.S., Waraska K., Mitchell B.S., and Wright D.G. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. Leukemia Res 28 (2004) 1125-1136
33. Mechtersheimer G., Egerer G., Hensel M., Rieker R.J., Libicher M., Lehnert T., et al. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch 444 (2004) 108-118
34. Nagai M., Natsumeda Y., Konno X., Hoffman R., Irino S., and Weber G. Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res 51 (1991) 3886-3890
35. Nagai M., Natsumeda Y., and Weber G. Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res 52 (1992) 258-261
36. Natsumeda Y., Yamada Y., Yamaji Y., and Weber G. Synergistic cytotoxic effect of tiazofurin and ribavirin in hepatoma cells. Biochem Biophys Res Commun 153 (1988) 321-327
37. Olah E., Natsumeda X., Ikegami T., Kote Z., Horanyi M., Szelenyi J., et al. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K562 leukemia cells. Proc Natl Acad Sci USA 85 (1988) 6533-6537
38. Olah E., Ezer R., Giaretti W., and Eble J. Metabolic control of oncogene expression. Biochem Soc Trans 18 (1989) 72-74
39. Olah E., Kote Zs., Natsumeda Y., Yamaji Y., Jarai G., Lapis E., et al. Down-regulation of c-myc and c-Ha-ras gene expression by tiazofurin in rat hepatoma cells. Cancer Biochem Biophys 11 (1990) 107-117
40. Olah E., Csokay B., Prajda N., Jarai-Kote Zs., Yeh Y.A., and Weber G. Molecular mechanisms in the antiproliferative action of taxol and tiazofurin. Anticancer Res 16 (1996) 2469-2478
41. Orban T., Olah E., and Weber G. Ribavirin (Riba) is antiproliferative and oncolytic; it down-regulates c-myc expression and signal transduction, causes apoptosis and induced differentiation. Proc Am Assoc Cancer Res 43 (2002) 967
42. Pegram M.D., Koneczny G., and Slamon D.J. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat. Res 103 (2000) 57-75
43. Pelengaris S., Littlewood T., Khan M., Elia G., and Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3 (1999) 565-577
44. Pelengaris S., Khan M., and Evan Gl. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109 (2002) 321-334
45. Prajda N., Hata Y., Abonyi M., Singhal R.L., and Weber G. Sequential impact of tiazofurin and ribavirin on enzymic program of the bone marrow. Cancer Res 53 (1993) 5982-5986
46. Shen F., and Weber G. Tamoxifen downregulates signal transduction and is synergistic with Tiazofurin in human breast carcinoma MDA-MB-435 cells. Oncology Res 10 (1998) 325-331
47. Shen F., Xue X., and Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res 19 3A (1999) 1657-1662
48. Taniki T., Prajda N., Monden Y., and Weber G. Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells. Cancer Biochem Biophys 13 (1993) 295-302
49. Timar J., Tovari J., Pogany G., Ladanyi A., Paku S., Rso E., et al. The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells. Eur J Cancer 32A 1 (1996) 152-159
50. Tricot G.J., Jayaram H.N., Nichols C.R., Pennington K., Lapis E., Weber G., et al. Hematological and biochemical action of tiazofurin in a case of refractory acute myeloid leukemia. Cancer Res 47 (1987) 4988-4991
51. Tricot G.J., Jayaram H.N., Lapis E., Natsumeda Y., Nichols C.R., Kneebone P., et al. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity. Cancer Res 49 (1989) 3696-3701
52. Tricot G., Jayaram H.N., Weber G., and Hoffman R. Tiazofurin: biological effects and clinical uses. Intl J Cell Clon 8 (1990) 161-170
53. Tricot G., and Weber G. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with tiazofurin, a selective locker of inosine 5′-phosphate dehydrogenase activity. Anticancer Res 16 (1996) 3341-3347
54. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
55. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes Memorial Lecture. Cancer Res 43 (1983) 3466-3492
56. Weber G. Down-regulation of increased signal transduction capacity in human cancer cells. Adv Enzyme Regul 45 (2005) 37-51
57. Weber G., Nagai M., Natsumeda Y., Eble J.N., Jayaram H.N., Paulik E., et al. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient. Cancer Commun 3 (1991) 61-66
58. Weber G., Nakamura H., Natsumeda Y., Szekeres T., and Nagai M. Regulation of GTP biosynthesis. Adv Enzyme Regul 32 (1992) 57-69
59. Weber G., Shen F., Prajda N., Yang H., Li W., Csokay B., et al. Regulation of the signal transduction program by drugs. Adv Enzyme Regul 37 (1997) 35-55
60. Weber G., Shen F., Prajda N., and Abonyi M. Down-regulation by drugs of the increased signal transduction in cancer cells. Adv Enzyme Regul 40 (2000) 19-34
61. Weber G., Shen F., Orbán T.I., Kökény Sz., and Olah E. Targeting signal transduction. Adv Enzyme Regul 43 (2003) 47-56
62. Weinstein I.B. Cancer. addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
63. Wright D.G., Boosalis M., Malek K., and Waraska K. Effects of the IMP-dehydrogenase inhibitor, tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies. Leukemia Res 28 (2004) 1137-1143
64. Yamada Y., Natsumeda Y., and Weber G. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase. Biochemistry 27 (1988) 2193-2196
65. Yeh Y.A., Olah E., Wendel J.J., Sledge G.W., and Weber G. Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule-dependence. Life Sci 54 (1994) 431-435